Correlation between anti-interferon-beta binding and neutralising antibodies in multiple sclerosis patients on interferon-beta therapy

被引：0
|
作者：
Jensen, P. E. H. [1 ]
Sellebjerg, F. [1 ]
Sondergaard, H. B. [1 ]
Sorensen, P. S. [1 ]
机构：
[1] Rigshosp, DK-2100 Copenhagen, Denmark
来源：
MULTIPLE SCLEROSIS JOURNAL | 2011年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P306
引用
收藏
页码：S120 / S120
页数：1
相关论文
共 50 条
  • [1] Interferon-beta neutralising antibodies in Canadian multiple sclerosis patients treated with different interferon-beta products
    Grossberg, S. E.
    Gehshan, A.
    Long, C.
    Chuppa, S. L.
    Nicholson, K.
    Grossberg, L. D.
    MULTIPLE SCLEROSIS, 2006, 12 : S207 - S208
  • [2] The measurement of antibodies binding to interferon-beta in Iranian multiple sclerosis patients treated with interferon-beta
    Jangouk, P
    Hooshmand, E
    Vaezeafshar, R
    Lotfi, J
    Amirzargar, A
    Nikbin, B
    JOURNAL OF NEUROLOGY, 2004, 251 : 64 - 64
  • [3] Neutralising antibodies to interferon-beta therapy in relapsing multiple sclerosis: a pilot study
    Lau, A. Y. L.
    Chan, E.
    Lau, K. K.
    Mok, V
    Siu, D. Y. W.
    Lee, R.
    HONG KONG MEDICAL JOURNAL, 2019, 25 (04) : 22 - 25
  • [4] Clinical utility of anti-interferon-beta antibodies in patients with multiple sclerosis
    Pietrzak, Anna
    Michalak, Slawomir
    Kozubski, Wojciech
    AKTUALNOSCI NEUROLOGICZNE, 2016, 16 (02): : 92 - 98
  • [5] A comparative study of development of anti-interferon-beta antibodies in a randomized study of interferon-beta 1b and interferon beta 1a in patients with multiple sclerosis
    Sorensen, PS
    Ross, C
    Koch-Henriksen, N
    Svenson, M
    Skovgaard, GL
    Bendtzen, K
    NEUROLOGY, 1999, 52 (06) : A491 - A491
  • [6] Persistent neutralising antibodies to interferon-beta and clinical outcomes in multiple sclerosis patients
    Costelloe, L.
    O'Rourke, K.
    Tubridy, N.
    Hutchinson, M.
    MULTIPLE SCLEROSIS, 2006, 12 : S205 - S205
  • [7] Anti-interferon-beta neutralising activity is not entirely mediated by antibodies
    Gilli, F
    Sala, A
    Hoffmann, F
    Marnetto, F
    Caldano, M
    Kappos, L
    Bertolotto, A
    Lindberg, RLP
    MULTIPLE SCLEROSIS, 2005, 11 : S2 - S3
  • [8] Neutralising Antibodies to Interferon-beta Therapy in Chinese Patients with Relapsing and Remitting Multiple Sclerosis.
    Ip, W. K.
    Lau, A. Y. L.
    Zhang, S.
    Au, C. C. K.
    Wong, W.
    Lau, K. K.
    Li, P.
    Chan, E. Y. T.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (03) : 416 - 417
  • [9] Neutralising antibodies against interferon-beta neutralise natural interferon-beta
    Sominanda, A.
    Menge, T.
    Hemmer, B.
    Hartung, H. P.
    Kieseier, B. C.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S134 - S134
  • [10] Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis
    Polman, Chris H.
    Bertolotto, Antonio
    Deisenhammer, Florian
    Giovannoni, Gavin
    Hartung, Hans-Peter
    Hemmer, Bernhard
    Killestein, Joep
    McFarland, Henry F.
    Oger, Joel
    Pachner, Andrew R.
    Petkau, John
    Reder, Anthony T.
    Reingold, Stephen C.
    Schellekens, Huub
    Sorensen, Per Soelberg
    LANCET NEUROLOGY, 2010, 9 (07): : 740 - 750
12345